negative side effects of glp 1 agonists GLP-1 Effects: A Complete Guide to What You Can Expect The cardiovascular effects of GLP-1

Indian J Med Res (2020) 151:11

Approval for treatment is not guaranteed

Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%

Healthcare providers need to overcome barriers related to the shortage and mitigate undesired negative consequences from an inability of patients with type 2 diabetes mellitus to obtain GLP-1 receptor agonist therapies amid this global access challenge

Proteotypic peptides were used for protein group quantification, under double-pass mode neural network configuration

In the landmark SELECT trial in 2023, the scope of GLP-1RAs was expanded to assess cardiovascular risk in patients with preexisting cardiovascular disease who were overweight or obese without type 2 diabetes [48]